Veru Inc. Showcases Innovative Therapies At Healthcare Conference
$VERU
Veru Inc. (NASDAQ:VERU), clinical stage biopharmaceutical company, recently announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas, Nevada. Mitchell Steiner, M.D., Chairman, President and CEO of Veru, will engage in a fireside chat on April 9, 2025, highlighting the company’s advancements in developing treatments for cardiometabolic and inflammatory diseases. The company’s drug development program is currently focused on two innovative molecules: enobosarm and sabizabulin.
Enobosarm, a selective androgen receptor modulator (SARM), is designed to enhance weight reduction therapies by making them more tissue selective, thus preserving lean mass while promoting fat loss. This drug is in a Phase 2b QUALITY clinical study aimed at evaluating its effectiveness in obese or overweight older adults using semaglutide, a medication approved for weight management. The study showed a statistical preservation of total lean body mass in patients treated with enobosarm in combination with semaglutide compared to those receiving semaglutide alone.
On another front, Veru is exploring sabizabulin for the treatment of inflammation in atherosclerotic cardiovascular disease. This novel oral agent has shown potential in preclinical studies to reduce inflammation. The company plans to initiate a Phase 2 study to further investigate sabizabulin’s efficacy in reducing coronary plaque volume, an important marker of cardiovascular health.
These developments represent significant steps forward in Veru’s commitment to addressing unmet medical needs through innovative therapies. The company’s focus on diseases that are major causes of morbidity and mortality worldwide underscores its role in potentially improving patient outcomes in areas with critical needs. The ongoing research and upcoming trials will be crucial in determining the future directions and potential approvals of these promising treatments.
**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**